1. Home
  2. HRTX vs RNTX Comparison

HRTX vs RNTX Comparison

Compare HRTX & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heron Therapeutics Inc.

HRTX

Heron Therapeutics Inc.

HOLD

Current Price

$0.30

Market Cap

61.2M

Sector

Health Care

ML Signal

HOLD

Logo Rein Therapeutics Inc.

RNTX

Rein Therapeutics Inc.

BUY

Current Price

$0.58

Market Cap

54.2M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
HRTX
RNTX
Founded
1983
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.2M
54.2M
IPO Year
2007
2017

Fundamental Metrics

Financial Performance
Metric
HRTX
RNTX
Price
$0.30
$0.58
Analyst Decision
Hold
Buy
Analyst Count
2
2
Target Price
N/A
★ $6.00
AVG Volume (30 Days)
★ 2.2M
417.8K
Earning Date
11-03-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 44.16
EPS
★ N/A
N/A
Revenue
★ $154,904,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 7.36
N/A
52 Week Low
$0.26
$0.54
52 Week High
$1.58
$2.18

Technical Indicators

Market Signals
Indicator
HRTX
RNTX
Relative Strength Index (RSI) 40.45 37.04
Support Level $0.29 $0.54
Resistance Level $0.34 $0.87
Average True Range (ATR) 0.04 0.06
MACD -0.01 -0.01
Stochastic Oscillator 8.20 15.78

Price Performance

Historical Comparison
HRTX
RNTX

About HRTX Heron Therapeutics Inc.

Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: